EASD 2025 15 - 19 September 2025

REDEFINE 1: A randomised study of combined semaglutide 2.4 mg and cagrilintide 2.4 mg for the treatment of overweight or obesity in adults

Authors :

W. Timothy Garvey¹; Matthias Blüher²; Cynthia Karenina Osorto Contreras³; Melanie J. Davies⁴; Eva Winning Lehmann³; Kirsi H. Pietiläinen⁵; Domenica Rubino⁶; Paolo Sbraccia⁷; Lisa von Huth Smith³; Thomas Wadden⁸; Niels Zeuthen³; John Wilding⁹

Affiliations

View Details Hide Details

Keywords

Obesity

Congress oral presentation

GLP-1 RA

CagriSema

PHASE 3 (RCT)

Search Science Hub

Are you a healthcare professional?

REDEFINE 1: A randomised study of combined semaglutide 2.4 mg and cagrilintide 2.4 mg for the treatment of overweight or obesity in adults